Research impact

Each year over 6,700 Australian women and girls are diagnosed with gynaecological cancer and this number is increasing annually and almost a third will not survive their disease. Gynaecological cancers are the third most commonly diagnosed cancer among Australian women.

Established in 2012, Cherish has fundraised over $2million and we keep growing our efforts because we need to increase research investment to beat gynaecological cancer and help all the women in our lives.

We have a clear vision to transform the standard care of women and girls diagnosed with gynaecological cancer from rigid, institution-centred methods to a contemporary, personalised informed approach with research to be conducted and then implemented into clinical practice.

Cherish has helped fund some breakthrough clinical trials which have improved women’s lives through fewer hospital bed days, less radical surgery and complications, lower treatment costs and providing choice to women to retain fertility options. Direct benefits to trial participants have included up-to-date, best practice care, personalised treatment approaches, close monitoring, and the opportunity to benefit from new treatment options.

Below are some of our current research projects and breakthroughs that Cherish has helped to fund.

We can’t do it alone – help us to fund research that will save lives.

Your support and assistance with funding enables Cherish to support breakthroughs and success in medical research for gynaecological cancer – please donate today.

Institute overheads and indirect costs will not be funded.

feMMe Molecular - a non-surgical alternative to hysterectomy for the treatment of endometrial cancer.

feMMe Molecular

ENDO-3 - a world-first randomised clinical trial investigating the risks and benefits of sentinel node biopsy.


feMMe - improving the treatment for women with early-stage endometrial cancer

feMMe Trial

IMAGE - improving clinical management of ovarian cancer


LACE - less invasive surgery for hysterectomies

LACE Trial


Pre-ANVU Study